Dulaglutide vs KPV
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Dulaglutide
Dulaglutide (Trulicity) is a once-weekly GLP-1 receptor agonist for type 2 diabetes. Its larger molecular size from fusion with an Fc fragment extends half-life and may reduce some GI side effects.
Full details →KPV
KPV is a tripeptide (Lys-Pro-Val) derived from alpha-melanocyte-stimulating hormone (α-MSH). It retains the potent anti-inflammatory properties of the parent hormone without the tanning or other melanocortin effects.
Full details →Side-by-Side Comparison
| Aspect | Dulaglutide | KPV |
|---|---|---|
| Mechanism | GLP-1 analog fused to a modified human IgG4 Fc fragment, providing extended duration of action. Activates GLP-1 receptors for glucose-dependent insulin secretion and appetite suppression. | Inhibits NF-κB activation and reduces inflammatory cytokine production. Enters cells and directly modulates inflammatory signaling without requiring melanocortin receptors. |
| Typical Dosage | Start at 0.75mg once weekly, may increase to 1.5mg, 3mg, or maximum 4.5mg weekly based on glycemic response. | Oral/sublingual: 200-500mcg 1-3 times daily. Topical formulations for localized inflammation. Also used in enemas for gut inflammation. |
| Administration | Subcutaneous injection once weekly, any time of day, with or without food. Comes in pre-filled single-dose pens. | Can be taken orally, sublingually, or as suppositories/enemas for gut inflammation. Topical use for skin conditions. Stable orally unlike most peptides. |
| Side Effects | Nausea, diarrhea, vomiting, abdominal pain, decreased appetite. Generally well-tolerated with gradual dose titration. | Generally very well-tolerated. Minimal systemic effects due to targeted anti-inflammatory action. |
| Best For |